TScan Therapeutics to present data from ongoing ALLOHA Phase 1 trial at ASH

TScan Therapeutics (TCRX) “announced that updated results from the ongoing ALLOHA Phase 1 trial of TSC-100 and TSC-101 will be presented during an oral session at the 66th American Society of Hematology, ASH, Annual Meeting and Exposition. TSC-100 and TSC-101 are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation with reduced intensity conditioning. In the ongoing ALLOHA Phase 1 trial, patients receive either TSC-100 or TSC-101 post-HCT, whereas control-arm patients receive HCT alone as per standard of care. To date, 38 patients have been enrolled in the trial and undergone HCT, with 26 in the treatment arm and 12 in the control arm. The key endpoints in the trial are safety and efficacy, with exploratory endpoints including donor chimerism and minimal residual disease, MRD, status. To date, event-free survival strongly favors the treatment arm and early trends suggest a lower probability of relapse. TSC-100 and TSC-101 infusions were well-tolerated at all three dose levels with no dose-limiting toxicities. Observed adverse events were similar across the treatment and control arms and were generally consistent with post-HCT adverse events. TSC-100 and TSC-101 TCR-T cells were detected at all timepoints in all treated patients, including those who have been on study for over a year, with clear evidence of a dose-persistence relationship.”